Merck to buy cancer drug developer in deal that could be worth more than $2B
May 21, 2019 at 09:00 AM EDT
Merck's deal for Dallas-based Peloton Therapeutics includes an upfront payment of $1.05 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|